Cytokines in psoriasis

International Journal of Dermatology

Volumn 38, Issue 4, 1999, Pages 241-251

  Bonifati, Claudio ^a   Ameglio, Franco ^a  

^a SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; CELL ADHESION MOLECULE; CHEMOKINE; COMPLEMENT COMPONENT C5A; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; ERYTHROPOIETIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; LEUKOTRIENE; PROSTAGLANDIN; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANGIOGENESIS; CELL INTERACTION; CELL PROLIFERATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENDOTHELIUM CELL; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; KERATINOCYTE; PSORIASIS; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

CYTOKINES; HUMANS; PSORIASIS; SKIN;

EID: 0032943056     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.1999.00622.x     Document Type: Review

References (119)

1. Baker BS, Fry L. The immunology of psoriasis. Br J Dermatol 1992; 126: 1-9.
2. Wrone-Smith, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Invest Dermatol 1996; 98: 1878-1887.
3. Gilhar A, David M, Ullman Y, et al. T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice. J Invest Dermatol 1997; 109: 283-288.
4. Barker JNWN, Mitra RS, Griffiths CEM, et al. Keratinocytes as initiators of inflammation. Lancet 1991; 337: 211-214.
5. Nickoloff BJ. The cytokine network in psoriasis. Arch Dermatol 1991; 127: 871-884.
6. Williams IR, Kupper TS. Immunity at the surface: homeostatic mechanisms of the skin immune system. Life Sci 1996; 58: 1485-1507.
7. Dinarello CA, Wolff Sheldon M. The role of interleukin-1 in disease. N Engl J Med 1993; 328: 106-113.
8. Zepter K, Haffner A, Soohoo LF, et al. Induction of biologically active IL-1beta-converting enzyme and mature IL-1beta in human keratinocytes by inflammatory and immunologic stimuli. J Immunol 1997; 159: 6203-6208.
9. Mizutani HR, Black R, Kupper TS. Human keratinocytes produce but not process pro-IL-1beta: different strategies of IL-1 production and processing in monocytes and keratinocytes. J Clin Invest 1991; 87: 1966-1971.
10. Cooper KD, Hammerberger C, Baadsgaard O, et al. IL-1 activity is reduced in psoriatic skin. Decreased IL-1alpha and increased nonfunctional IL-1beta. J Immunol 1990; 144: 4593-4603.
11. Debets R, Hengmans JPJJ, Troost RJJ, et al. Enhanced production of biologically active interleukin-1alpha and interleukin-1beta by psoriatic epidermal cells ex vivo: evidence of increased cytosolic interleukin-1beta levels and facilitated interleukin-1 release. Eur J Immunol 1995; 25: 1624-1630.
12. Gruaz D, Didierjean L, Grassi J, et al. Interleukin 1 alpha and beta in psoriatic skin: enzymeimmunoassay, immunoblot studies and effect of systemic retinoid. Dermatologica 1989; 179: 202-206.
13. Prens EP, Van Damme J, Bakkus M, et al. Interleukin-1 and interleukin-6 in psoriasis. J Invest Dermatol 1990; 95: 121S-124S.
14. Romero LI, Ikejima T, Pincus SH. In situ localization of interleukin-1 in normal and psoriatic skin. J Invest Dermatol 1989; 93: 518-522.
15. Kristensen M, Deleuran B, Eedy DJ, et al. Distribution of interleukin 1 receptor antagonist protein and interleukin 1 alpha in normal and psoriatic skin. Decreased expression of IRAP in psoriatic lesional epidermis. Br J Dermatol 1992; 127: 305-311.
16. Bonifati C, Ameglio F, Carducci M, et al. Interleukin-1-beta, interleukin-6 and interferon-gamma in suction blister fluids of involved and uninvolved skin and sera of psoriatic patients. Acta Derm Venereol (Stockh) 1994; (Suppl. 186): 23-24.
17. Debets R, Hegmans JPJJ, Croughs P, et al. The IL-1 system in psoriatic skin. IL-1 antagonist sphere of influence in lesional psoriatic epidermis. J Immunol 1997; 158: 2955-2963.
18. Bonifati C, Carducci M, Mussi A, et al. IL-1alpha and IL-1beta and psoriasis: conflicting results in the literature. Opposite behaviour of the two cytokines in lesional or non-lesional extracts of whole skin. J Biol Regul Homeost Agents 1997; 11: 133-136.
19. Dinarello CA. Role of pro- and anti-inflammatory cytokines during inflammation: experimental and clinical findings. J Biol Regul Homeost Agents 1997; 11: 91-103.
20. Groves RW, Ross E, Barker JNWN, et al. Effect of in vivo interleukin-1 on adhesion molecule expression in normal human skin. J Invest Dermatol 1992; 98: 384-387.
21. Luger TA, Kock A, Danner M. Production of distinct cytokines by epidermal cells. Br J Dermatol 1985; (Suppl. 28): 145-156.
22. Heufler C, Kock F, Schuler G. Granulocyte/macrophage colony stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J Exp Med 1988; 167: 700-705.
23. Delaporte E, Bieber T, Viac J, et al. Cytokines épidermique et inflammation cutanée. Ann Dermatol Venereol 1994; 121: 836-843.
24. Zhang YHJX, Lin YKY, Vilcek J. Synthesis of interleukin 1 (interferon-beta 2/B cell stimulatory factor 2) in human fibroblasts is triggered by an increase in intracellular cyclic AMP. J Biol Chem 1988; 264: 6177-6182.
25. Ristow HJ. A major factor contributing to epidermal proliferation in inflammatory skin diseases appears to be interleukin 1 or a related protein. Proc Natl Acad Sci USA 1987; 84: 1940-1944.
26. Groves RW, Mizutani H, Kieffer JD, Kupper TS. Inflammatory skin disease in transgenic mice that express high levels of interleukin-1alpha in basal epidermis. Proc Natl Acad Sci USA 1995; 92: 11874-11878.
27. Takematsu H, Ohta H, Tagami H. Absence of tumor necrosis factor-alpha in suction blister fluids and stratum corneum from patients with psoriasis. Arch Dermatol Res 1989; 281: 398-400.
28. Nickoloff BJ, Karabin GD, Barker JNWN, et al. Cellular localization of interleukin-8 and its inducer tumor necrosis factor in psoriasis. Am J Pathol 1991; 138: 129-140.
29. Ettehadi P, Greaves W, Wallach D, et al. Elevated tumor necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96: 146-151.
30. Bonifati C, Carducci M, Cordiali-Fei P, et al. Correlated increases of tumor necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients: relationships with disease severity. Clin Exp Dermatol 1994; 19: 383-387.
31. Mussi A, Bonifati C, Carducci M, et al. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 1997; 11: 115-118.
32. Hohler T, Kruger A, Schneider PM, et al. A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J Invest Dermatol 1997; 109: 562-565.
33. Olaniran AK, Baker BS, Paige DG, et al. Cytokine expression in psoriatic skin lesions during PUVA therapy. Arch Dermatol Res 1996; 288: 421-425.
34. Wakefield PE, James WD, Samlaska CP, Meltzer MS. Tumor necrosis factor. J Am Acad Dermatol 1991; 24: 675-685.
35. Aggarwal BB, Natarajan K. Tumor necrosis factors: developments during the last decade. Eur Cytokine Netw 1996; 7: 93-124.
36. Barker JNW, Sarma V, Mitra RS, et al. Marked synergism between tumor necrosis factor-alpha and interferon-gamma in regulation of keratinocyte-derived adhesion molecule and chemotactic factors. J Clin Invest 1990; 85: 605-608.
37. Groves RW, Allen MH, Ross EL, et al. Tumor necrosis factor alpha is pro-inflammatory in normal human skin and modulates cutaneous adhesion molecule. Br J Dermatol 1995; 132: 345-352.
38. Ameglio F, Bonifati C, Pietravalle M, Fazio M. Interleukin-6 and tumor necrosis factor levels decrease in the suction blister fluids of psoriatic patients during effective therapy. Dermatology 1994; 189: 359-363.
39. Schubert C, Christophers E. Mast cells and macrophages in early relapsing psoriasis. Arch Dermatol Res 1984; 277: 352-358.
40. Christophers E. The immunopathology of psoriasis, Int Arch Allergy Immunol 1996; 110: 199-206.
41. Baadsgaard O, Fisher G, Voorhees JJ, Cooper KD. The role of the immune system in the pathogenesis of psoriasis. J Invest Dermatol 1990; 95: 32S-34S.
42. Baadsgaard O, Fisher GJ, Voorhees JJ, Cooper KD. Interactions of epidermal cells and T cells in inflammatory skin diseases. J Am Acad Dermatol 1990; 23: 1312-1317.
43. Romagnani S. Human TH1 and TH2 subsets: "Eppur si muove!". Eur Cytokine Netw 1994; 5: 7-12.
44. O'Garra A. Interleukins and the immune system. Lancet 1989; ii: 943-946.
45. Wilkinson PC, Newman I. Chemoattractant activity of IL-2 for human lymphocytes: a requirement for the IL-2 receptor beta-chain. Immunology 1994; 1: 134-139.
46. Della Casa Alberighi O. Ciclosporina. It Gen Rev Dermatol 1994; 31: 241-263.
47. Wong RL, Winslow CM, Cooper KD. The mechanisms of action of cyclosporin A in the treatment of psoriasis. Immunol Today 1993; 14: 69-74.
48. Lee RE, Gaspari AA, Lotze MT, et al. Interleukin 2 and psoriasis. Arch Dermatol 1988; 124: 1811-1815.
49. Uyemura K, Yamamura M, Fivenson DF, et al. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 1993; 101: 701-705.
50. Schlaak JF, Buslau M, Jochum W, et al. T cells involved in psoriasis vulgaris belong to the th1 subset. J Invest Dermatol 1994; 102: 145-149.
51. Barna M, Bos JD, Kapsenberg ML, Snijdewint FGM. Effect of calcitriol on the production of T-cell-derived cytokines in psoriasis. Br J Dermatol 1997; 136: 536-541.
52. Nickoloff BJ. Role of interferon-gamma in cutaneous trafficking of lymphocytes with emphasis on molecular and cellular adhesion events. Arch Dermatol 1988; 124: 1835-1842.
53. Knopp J. Immunologic effects of interferon. J Invest Dermatol 1990; 95: 72S-74S.
54. Gottlieb AB, Luster AD, Posnett DN, Carter DM. Detection of a gamma-interferon-induced protein IP-10 in psoriatic plaque. J Exp Med 1988; 168: 941-948.
55. Basham TY, Nickiloff BJ, Merigan TC, Morhenn VB. Recombinant gamma interferon induces HLA-DR expression on cultured human keratinocytes. J Invest Dermatol 1984; 83: 88-92.
56. Fierlbeck G, Rasser G, Muller C. Psoriasis induced at the injection site of recombinant interferon gamma. Arch Dermatol Res 1990; 126: 351-355.
57. Barna M, Snijdewint FGM, van Der Heijden FL, et al. Characterization of lesional psoriatic skin T lymphocyte clones. Acta Derm Venereol (Stockh) 1900; (Suppl. 186): 9-11.
58. Vollmer S, Menssen A, Trommler P, et al. T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells. Eur J Immunol 1994; 24: 2377-2382.
59. Kagi MK, Wuthrich B, Ontano E, et al. Differential cytokine profiles in peripheral blood lymphocyte supernatants and skin biopsies from patients with different forms of atopic dermatitis, psoriasis and normal individuals, Int Arch Allergy Immunol 1994; 103: 332-340.
60. Harvima IT, Horsmanheimo L, Naukkarinen A, Horsmanheimo L. Mast cell proteinases and cytokines in skin inflammation. Arch Dermatol Res 1994; 287: 61-67.
61. Prens E, Hegmans J, Chin R, et al. Increased expression of interleukin-4 receptors on psoriatic epidermal cells. Am J Pathol 1996; 148: 1493-1502.
62. Hart PH, Vitti GF, Burgess DS, et al. Potential anti-inflammatory effects of interleukin-4; suppression of human monocyte tumor necrosis factor-alpha, interleukin-1, and prostaglandin E2. Proc Natl Acad Sci USA 1989; 86: 3803-3807.
63. Vannier E, Miller LC, Dinarello CA. Coordinated antinflammatory effects of interleukin-4: interleukin-4 suppresses interleukin-1 production but upregulates gene expression and synthesis of interleukin-1 receptor antagonist. Proc Natl Acad Sci USA 1900 89: 4076-4080.
64. Howard M, O'Garra A. Biological properties of interleukin 10. Immunol Today 1992; 13: 198-200.
65. Mussi A, Bonifati C, Carducci M, et al. IL-10 levels are decreased in psoriasis lesional skin as compared to the psoriatic lesion-free and normal skin suction blister fluids. J Biol Regul Homeost Agents 1994; 8: 117-120.
66. Nickoloff BJ, Fivenson DP, Kunkel SL, et al. Keratinocyte interleukin-10 expression is upregulated in tape-stripped skin, poison ivy dermatitis, and Sezary syndrome, but not in psoriatic plaque. Clin Immunol Immunopathol 1994; 73: 63-68.
67. Michel G, Mirmohammadsadegh A, Olasz E, et al. Demonstration and functional analysis of IL-10 receptors in human epidermal cells: decreased expression in psoriatic skin, down-modulation by IL-8, and up-regulation by an antipsoriatic glucocorticoid in normal cultured keratinocytes. J Immunol 1997; 159: 6291-6297.
68. Takatsu K. Interleukin-5. Curr Opin Immunol 1992; 4: 299-306.
69. Gearing DP. The leukemia inhibitory factor and its receptor. Adv Immunol 1993; 53: 31-58.
70. Grossman RM, Krueger J, Yourish D, et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA 1989; 86: 6367-6371.
71. Paquet P, Pièrard GE. Interleukin-6 and the skin. Int Arch Allergy Immunol 1996; 109: 308-317.
72. Ameglio F, Bonifati C, Fazio M, et al. Interleukin-11 production is increased in organ cultures of lesional skin of patients with plaque-type psoriasis as compared with nonlesional and normal skin. Similar to interleukin-1beta, interleukin-6 and interleukin-8. Arch Dermatol Res 1997; 289: 399-403.
73. Bonifati C, Mussi A, D'Auria L, et al. Spontaneous release of leukemia inhibitory factor and oncostatin-M is increased in supernatants of short-term cultures from lesional psoriatic skin. Arch Dermatol Res 1998; 290: 9-13.
74. Hirano T, Akira S, Taga T, Kishimoto T. Biological and clinical aspects of interleukin-6. Immunol Today 1990; 11: 443-449.
75. Bonifati C, Solomone M, Trento E, et al. Serum disease-6 levels as an early marker of therapeutic response to UVB radiation and topical steroids in psoriatic patients. Int J Clin Lab Res 1994; 24: 122-123.
76. Villiger PM, Geng Y, Lotz M. Induction of cytokine expression by leukemia inhibitory factor. J Clin Invest 1993; 91: 1571-1581.
77. Metcalf D. The leukemia inhibitory factor (LIF). Int J Cell Cloning 1991; 9: 95-108.
78. Paglia D, Kondo S, Sauder DN. A novel endogenous mediator of cutaneous inflammation: leukemia inhibitory factors. Acta Derm Venereal (Stockh) 1996; 76: 111-114.
79. Callard R, Gearing A. OSM. In: Cytokine Facts Book. Academic Press, Harcourt Brace 1994: 207-209.
80. Brown TJ, Liu J, Brashem-Stein C, Shoyab M. Regulation of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor expression by oncostatin M. Blood 1993; 82: 33-37.
81. Brown TJ, Rowe JM, Liu JW, Shoyab M. The regulation of IL-6 expression by oncostatin M. J Immunol 1991; 147: 2175-2180.
82. Leng X, Elias JA. Interleukin-11 inhibits macrophage interleukin-12 production. J Immunol 1997; 159: 2161-1168.
83. Takematsu H, Tagami H. Granulocyte-macrophage colony-stimulating factor in psoriasis. Dermatologica 1990; 181: 16-20.
84. Weisbart RH, Golde DW, Gasson JC, et al. Human granulocyte-macrophage colony stimulating factor is a neutrophil activator. Nature 1985; 314: 361-363.
85. Hancock GE, Kaplan G, Cohn ZA. Keratinocyte growth regulation by the products of immune cells. J Exp Med 1988; 168: 1395-1402.
86. Kelly RI, Marsden RA. Exacerbation of psoriasis with GM-CSF therapy. Br J Dermatol 1993; 128: 468-469.
87. Costello R, Imbert J, Olive D. Interleukin-7 a major T-lymphocyte cytokine. Eur Cytokine Netw 1993; 4: 253-262.
88. Priti TM, Grant JA, Siegel JP. Synergistic effect of IL-7 and IL-12 on human T cell activation. J Immunol 1995; 154: 5093-5102.
89. Sieling PA, Sakimura L, Uyemura K, et al. IL-7 in the cell-mediated immune response to a human pathogen. J Immunol 1995; 154: 2775-2783.
90. Bonifati C, Trento E, Cordiali-Fei P, et al. Increased interleukin-7 concentrations in lesional skin and in the sera of patients with plaque-type psoriasis. Clin Immunol Immunopathol 1997; 83: 41-44.
91. Nickoloff BJ, Mitra RS, Varani J, et al. Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 1994; 144: 820-828.
92. Kostantinova N, Duong DMT, Remenyik E, et al. Interleukin-8 is induced in skin equivalents and is highest in those derived from psoriatic fibroblasts. J Invest Dermatol 1996; 107: 615-621.
93. Gillitzer R, Berger R, Mielke V, et al. Upper keratinocytes of psoriatic skin lesions express high levels of NAP-1/IL-8 mRNA in situ. J Invest Dermatol 1991; 97: 73-79.
94. Beljaards RC, Van Beek P, Nieboer C, et al. The expression of interleukin-8 receptor in untreated and treated psoriasis. Arch Dermatol Res 1997; 289: 440-443.
95. Gillitzer R, Ritter U, Spandau U, et al. Differential expression of GRO-alpha and IL-8 mRNA in psoriasis: a model for neutrophil migration and accumulation in vivo. J Invest Dermatol 1996; 107: 778-782.
96. Kojima T, Cromie MA, Fisher GJ, et al. GRO-alpha mRNA is selectively overexpressed in psoriatic epidermis and is reduced by cyclosporin A in vivo, but not in cultured keratinocytes. J Invest Dermatol 1993; 101: 767-772.
97. Gillitzer R, Wolff K, Tong D. MCP-1 mRNA expression in basal keratinocytes of psoriatic lesions. J Invest Dermatol 1993; 101: 127-131.
98. Kemény L, Ruzicka T, Dobozy A, Michel G. Role of interleukin-8 receptor in skin. Int Arch Allergy Immunol 1994; 104: 317-322.
99. Barker JNWN, Jones ML, Mitra RS, et al. Modulation of keratinocyte-derived interleukin-8 which is chemotactic for neutrophils and T lymphocytes. Am J Pathol 1991; 4: 869-876.
100. Tuschil A, Lam C, Halsberger A, Lindley I. Interleukin-8 stimulates calcium transients and promotes epidermal cell proliferation. J Invest Dermatol 1991; 99: 294-298.
101. Haskill S, Peace A, Morris J, et al. Identification of three related genes encoding cytokine functions. Proc Natl Acad Sci USA 1990; 87: 7732-7736.
102. Nanney LB, Stosceck C, King LE. Active psoriatic lesions contain increased levels of epidermal growth factor (EGF) receptors. J Invest Dermatol 1985; 84: 290.
103. King LE, Gates RE, Stoscheck CM, Nanney LB. Epidermal growth factor/transforming growth factor alpha receptors and psoriasis. J Invest Dermatol 1990; 95: 10S-12S.
104. Elder JT, Fischer GJ, Lindquist PB, et al. Overexpression of transforming growth factor alpha in psoriatic epidermis. Science 1989; 243: 811-814.
105. Nanney LB, Stoscheck CM, Magid M, King LE Jr. Altered (125II) epidermal growth factor binding and receptor distribution in psoriasis. J Invest Dermatol 1986; 86: 260-265.
106. Krane JF, Gottlieb AB, Carter DM, Krueger JG. The insulin like growth actor I receptor is overexpressed in psoriatic epidermis, but is differentially regulated from the epidermal growth factor receptor. J Exp Med 1992; 175: 1081-1090.
107. Watts PA, Stables GS, Arkhurst RJ, Mackie RM. Localization of transforming growth factor-alpha RNA and protein in the skin of psoriatic patients receiving therapy. Br J Dermatol 1994; 131: 64-71.
108. Piepkorn M. Overexpression of amphiregulin, a major autocrine factor for cultured human keratinocytes, in hyperproliferative skin diseases. Am J Dermatopathol 1996; 18: 165-171.
109. Cook PW, Piepkorn M, Clegg CH, et al. Transgenic expression of the human amphiregulin gene induces a psoriasis like phenotype. J Clin Invest 1997; 100: 2286-2294.
110. Kane JM, Knapp AM, Mansbrige JN, Hanawalt PC. Transforming growth factor-beta1 localization in normal and psoriatic keratinocytes in situ. J Cell 1990; 144: 114-150.
111. Shmid P, Cox D, McMaster GH, Itin P. In situ hybridization analysis of cytokine, proto-oncogene and tumor gene expression in psoriasis. Arch Dermatol Res 1993; 285: 334-340.
112. Bonifati C, Carducci M, Mussi A, et al. The levels of transforming growth factor-beta1 are increased in the serum of patients with psoriasis and correlate with disease severity. Eur J Dermatol 1996; 6: 486-490.
113. Rubany GM, Polakoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology and pathophysiology. Pharmacol Rev 1994; 46: 325-415.
114. Trevisan G, Stinco G, Giansante C, et al. Psoriasis and endothelins. Acta Derm Venereol (Stockh) 1994; 186: 139-140.
115. Cecchi R, Giomi A, Ciuti M, et al. Increased levels of plasma endothelin-1 in patients with psoriasis. Clin Chim Acta 1994; 226: 113-115.
116. Bonifati C, Mussi A, Carducci M, et al. Endothelin-1 levels are increased in sera and lesional skin extracts of psoriatic patients and correlate with disease severity. Acta Derm Venereol (Stockh) 1998; 78: 22-26.
117. Bagnato A, Venuti A, Di Castro V, Marcante ML. Identification of ETA receptor subtype that mediates endothelin induced autocrine proliferation of normal human keratinocytes. Biochem Biophys Res Commun 1995; 209: 80-86.
118. Wright CD, Cody WL, Dumbar JB Jr, et al. Characterization of endothelins as chemoattractants for human neutrophils. Life Sci 1994; 55: 1633-1641.
119. Giacalone B, D'Auria L, Ferraro C, et al. Bullous pemphigoid blisters of the same duration have similar cytokine concentrations which decrease in older blisters. Br J Dermatol 1998; 139: 158-159.